Abstract
Background: There is minimal information available about acute hepatic porphyrias (AHPs) in developing countries. The aim of this study was to describe the demographics, clinical features, and mortality of AHPs in Colombia.
Patients and methods: 121 patients with presumed diagnosis of AHPs were reported in Colombia between 1944 and 2018. A pooled analysis of 53 patients with confirmed diagnosis was performed to evaluate the demographics, clinical features, and mortality of AHPs in the country. Selected variables were compared by periods (1952–2000 and 2001–2018).
Results: Most attacks occurred in women (66%), with a women-to-man ratio of 39/14. 96% of the patients were diagnosed with AHPs between 15 and 40 years of age. Precipitants were identified in 71% of attacks and more than one precipitant in 41% of them. Drugs (85%) and infections (44%) were the most common precipitants. 11% of women had premenstrual attacks. Abdominal pain was the most common symptom (96%). Cortical blindness, posterior reversible encephalopathy syndrome, and rhabdomyolysis were described. 70% of attacks were confirmed by qualitative test only. 67% of attacks were treated with intravenous heme. The use of heme increased from 4 to 85% in the last two decades. Mortality decreased about twofold in relation to the increase in the use of heme. Severe motor neuropathy was associated with increased mortality. Gonadorelin analogues, heme prophylaxis, and orthotopic liver transplantation have been used to prevent recurrent attacks.
Conclusions: Diagnosis and treatment of AHPs in Colombia have improved in recent decades. However, there are still important shortcomings to address.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AHPs:
-
Acute hepatic porphyrias
- AIP:
-
Acute intermittent porphyria
- ALA:
-
Aminolevulinic acid
- ALAS1:
-
Aminolevulinic acid synthase 1
- DNA:
-
Deoxyribonucleic acid
- GnA:
-
Gonadorelin analogs
- HCP:
-
Hereditary coproporphyria
- HMBS:
-
Hydroxymethylbilane synthase
- NAPOS:
-
Norwegian Porphyria Centre
- OLT:
-
Orthotopic liver transplantation
- PBG:
-
Porphobilinogen
- PRES:
-
Posterior reversible encephalopathy syndrome
- RNA:
-
Ribonucleic acid
- VP:
-
Variegate porphyria
References
Aarsand AK, Villanger JH, Støle E et al (2011) European specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and reporting as assessed by an external quality assurance program. Clin Chem 57:1514–1523
Adams CD, Amaya PF (2014) Quadriparesis and rhabdomyolysis due to acute intermittent porphyria: case report. Acta Med Colomb 39:28
Andersson C, Innala E, Bäckström T (2003) Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in Northern Sweden. J Intern Med 254:176–183
Angel DI, Siza LM, Fonseca DJ et al (2010) Acute intermittent porphyria (AIP) identification by sequencing a mutation not previously reported, in patient from the city of Bogotá. Iatreia 23:4S
Argüello M, Vergara I, Mora MC et al (1978) Acute intermittent porphyia study of 23 cases. Acta Med Colomb 3:217–239
Balwani M, Wang B, Anderson K et al (2017) Acute hepatic porphyrias: recommendations for evaluation and long term management. Hepatology 66:1314–1322
Bhat JI, Qureeshi UA, Bhat MA (2010) Acute intermittent porphyria with transient cortical blindness. Indian Pediatr 47:977–978
Bissell DM, Anderson KE, Bonkovsky HL (2017) Porphyria. N Engl J Med 377:862–872
Bonkovsky HL, Maddukuri VC, Yazici C et al (2014) Acute hepatic porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 127:1233–1241
Buitrago J, Santa SV (2009) Acute intermittent porphyria presenting as spontaneous hemothorax. Biomedica 29:339–347
Bylesjö I, Wikberg A, Andersson C (2009) Clinical aspects of acute intermittent porphyria in northern sweden: a population-based study. Scand J Clin Lab Invest 69:612–618
Chen MC, Chang CJ, Lu YH et al (2015) R173W mutation of hydroxymethylbilane synthetase is associated with acute intermittent porphyria complicated with rhabdomyolysis. J Clin Gastroenterol 49:256–257
Chen B, Solis-Villa C, Erwin A et al (2018) Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria. J Inherit Metab Dis. https://doi.org/10.1007/s10545-018-0163-6
Contreras-Zúñiga E, Zuluaga-Martínez SX (2006) Porphyria and pregnancy: a case report Eduardo. Rev Colomb Obstet Ginecol 57:216–218
D’Avola D, López-franco E, Sangro B et al (2016) Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 65:776–783
Deacon AC, Elder GH (2011) ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol. 54:500–507
De Siervi A, Rossetti MV, Parera VE et al (1999) Acute intermittent porphyria:biochemical and clinical analysis in the argentinean population. Clin Chim Acta 288:263–271
Devars du Mayne JF, Deybach JC, Nordmann Y et al (1987) Rhabdomyolysis in acute intermittent porphyria. Presse Med 16:310
Doss MO (1987) Porphyrinurias and occupational disease. Ann N Y Acad Sci 514:204–218
Enríquez-marulanda A, Shinchi M, Granados AM et al (2016) Acute intermittent porphyria and it’s relationship with posterior reversible encephalopathy syndrome: case report. Acta Neurol Colomb 32:155–160
García-Martul M, Santana-Cabrera L, Santos-Moyano Z et al (2008) Rhabdomyolysis after correction of severe to an attack of acute intermittent porphyria. Nefrologia 28:563–564
Garg MK, Mohapatro AK, Dugal JS et al (1999) Cortical blindness in acute intermittent porphyria. J Assoc Physicians India 47:727–729
Hift RJ, Meissner PN (2005) An analysis of 112 acute porphyric attacks in Cape Town, South Africa. Medicine (Baltimore) 84:48–60
Innala E, Bäckström T, Bixo M (2010) Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 89(1):95–100
Jaramillo-Calle DA (2017) Porphyria. N Engl J Med 377:2100–2101
Jaramillo-Calle DA, Castaño O, Marín JI et al (2018) Is liver transplantation for intractable attacks of porphyria a viable treatment in a developing country? Hepatology 67:802–803
Jeans JB, Savik K, Gross CR (1996) Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 65:269–273
Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria:occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71:1–13
Kupferschmidt H, Bont A, Schnorf H et al (1995) Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 123:598–600
Latorre G, Muñoz A (1988) Acute intermittent porphyria University Hospital San Vicente de Paul (1974-1987). Acta Med Colomb 13:443–451
Leung-Pineda V, Wilson DP (2017) Severe abdominal pain with hyponatremia. Clin Chem 63(9):1544–1554
Marsden JT, Peters TJ (2004) Rhabdomyolysis in a patient with acute intermittent porphyria. Ann Clin Biochem 41:341–343
Marsden JT, Rees DC (2010) A retrospective analysis of outcome of pregnancy in patients with acute porphyria. J Inherit Metab Dis 33:591–596
Marsden JT, Guppy S, Stein P et al (2015) Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep 22:57–65
Mendoza F, Pareja J, Zambrano R (1995) Hepatic porphyria with neurological manifestations. Acta Med Colomb 20:248–250
Mustajoki P, Koskelo P (1976) Hereditary hepatic porphyrias in Finland. Acta Med Scand 200:171–178
Mustajoki P, Nordmann Y (1993) Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153:2004–2008
Mykletun M, Aasne AK, Støle E et al (2014) Porphyrias in Norway. Tidsskr Nor Laegeforen 134:831–836
Olivier P, Van Melkebeke D, Honoré PJ et al (2017) Cerebral vasospasm in acute porphyria. Eur J Neurol 24:1183–1187
Ordoñez JH (1944) Acute porphyrinosis (clinical and electrocardiographic study). Anal Soc Biol Bogota 1:132–144
Pischik E, Bulyanitsa A, Kazakov V et al (2004) Clinical features predictive of a poor prognosis in acute porphyria. J Neurol 251:1538–1541
Pradilla G, Acevedo A, Martínez P (1980) Acute intermittent porphyria. Therapeutic advances in propanolol and hematin. Acta Neurol Colomb 5:642–651
Ramírez J (1959) Acute porphyria and pregnancy (topic review and case presentation). Rev Colomb Obstet Ginecol 10:428–441
Sardh E, Harper P, Al-Tawil N et al (2016) Interim data from a randomized, placebo controlled, phase 1 study of Aln-AS1, an investigational RNAi therapeutic for the treatment of acute hepatic porphyria. Blood 128:2318
Sardh E, Gouya L, Bloomer J et al (2017) Explore: a prospective, multinational natural history study of patients with acute hepatic porphyrias with recurrent attacks. Blood 130:2211
Schmitt C, Lenglet H, Yu A et al (2018) Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Intern Med. https://doi.org/10.1111/joim.12750
Schulenburg-Brand D, Gardiner T, Guppy S et al (2017) An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep 36:99–107
Soonawalla ZF, Orug T, Badminton MN et al (2004) Liver transplantation as a cure for acute intermittent porphyria. Lancet 363:705–706
Stein JA, Tschudy DP (1970) Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore) 49:1–16
Stein P, Badminton M, Barth J et al (2013) Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem 50:217–223
Uribe CU, Perez A, Guerra A et al (2007) Reversible angioespasm in acute intermittent porphyria and persistence of severe leukoencephalopathy. Acta Neurol Colomb 23:188
Whatley SD, Mason NG, Woolf JR et al (2009) Diagnostic strategies for autosomal dominant acute hepatic porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55:1406–1414
Willandt B, Langendonk JG, Biermann K et al (2015) Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series. JIMD Rep 25:77–81
Woolf J, Marsden JT, Degg T et al (2017) Best practice guidelines on first-line laboratory testing for porphyria. Ann Clin Biochem 54:188–198
Yasuda M, Bishop DF, Fowkes M et al (2010) AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol Ther 18:17–22
Yrjönen A, Pischik E, Mehtälä S et al (2008) A novel 19-Bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack. Clin Genet 74:396–398
Acknowledgment
We thank Jesenia Avendaño and Luis C. Hoyos for helping us obtain the articles.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Bruce A. Barshop, MD, PhD
Compliance with Ethics Guidelines
Conflict of Interest
Daniel A. Jaramillo-Calle and Daniel C. Aguirre Acevedo declare that they have no conflict of interest.
Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Details of the Contributions of Individual Authors
Daniel A. Jaramillo-Calle designed the study, analyzed and interpreted the data, and drafted and reviewed the article. He is guarantor for the article.
Daniel C. Aguirre Acevedo participated in the design of the study and had input for revising the article.
Funding
This study was funded by the IPS Universitaria Universidad de Antioquia.
Electronic Supplementary Material
Supplementary Material
(DOC 65 kb)
Rights and permissions
Copyright information
© 2018 Society for the Study of Inborn Errors of Metabolism (SSIEM)
About this chapter
Cite this chapter
Jaramillo-Calle, D.A., Aguirre Acevedo, D.C. (2018). Acute Hepatic Porphyrias in Colombia: An Analysis of 101 Patients. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 44. JIMD Reports, vol 44. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2018_125
Download citation
DOI: https://doi.org/10.1007/8904_2018_125
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-58616-7
Online ISBN: 978-3-662-58617-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)